Pharmafile Logo
Pharmafocus logo
Advanced Search

Janssen

Showing 15 posts of 276 posts found.

Janssen image

Janssen psoriasis drug beats placebo

March 25, 2014
Research and Development, Sales and Marketing Janssen, dermatology, guselkumab

News
Velcade image

NICE approves Velcade

March 21, 2014
Sales and Marketing Janssen, NHS, NICE, Velcade, myeloma

NICE has recommended Janssen’s proteasome inhibitor Velcade as an induction treatment for some patients with newly-diagnosed multiple myeloma. The draft …

News
Janssen image

FDA extends licence for Janssen’s Imbruvica

February 13, 2014
Sales and Marketing FDA, Janssen, durect, imbruvica, leukaemia

Janssen and partner Pharmacyclics have been given an extended FDA approval for their new blood cancer treatment Imbruvica. The US …

News

J&J: we’re proud to top social media leaderboard

January 27, 2014
Medical Communications, Sales and Marketing IMS, J&J, JJ, Janssen, digital, epatient, pharma

Johnson & Johnson says recognising the rise of the ePatient and being willing to share its corporate plans with the …

News
Janssen image

Imbruvica boost for Pharmacyclics

January 8, 2014
Sales and Marketing Janssen, Pharmacyclics, imbruvica

Pharmacyclics and Janssen Biotech have received a huge boost as a late-stage trial of their first-in-class, oral blood cancer drug …

News
janssen image

Janssen bets on stem cells

January 7, 2014
Research and Development, Sales and Marketing CDC, Janssen, Stem cells, cap, capricor

US biotech Capricor Therapeutics is being backed by Janssen Biotech to the tune of hundreds of millions of dollars to …

News
janssen image

FDA approves Olysio

November 25, 2013
Sales and Marketing FDA, Janseen, Janssen, hep C, hepc, olysio, simeprevir

US regulators have approved Janssen Pharmaceuticals’ Olysio, a new therapy to treat chronic hepatitis C virus infection, after a priority …

News
janssen image

Janssen/Pharmacyclics gain FDA nod for Imbruvica

November 14, 2013
Sales and Marketing FDA, Janssen, Pharmacyclics, Revlimid, Velcade

The FDA has approved Janssen and Pharmacyclics’ Imbruvica to treat patients with mantle cell lymphoma (MCL), a rare and aggressive …

News
J&J image

J&J hit with $2.2 billion fine

November 5, 2013
Sales and Marketing J&J, JJ, Janssen, Risperdal, antipsychotic, fine

Johnson & Johnson has admitted promoting its big-selling antipsychotic drug Risperdal off-label, costing the firm $2.2 billion in fines. The …

News
zytiga image

Janssen agrees Zytiga deal

October 14, 2013
Sales and Marketing AstraZeneca, Janssen, Zytiga

Janssen has agreed to co-promote its once-daily prostate cancer pill Zytiga with AstraZeneca in Japan for an undisclosed sum. A …

News
janssen image

Janssen takes on GSK hep C drug

October 9, 2013
Research and Development, Sales and Marketing GSK, GSK2336805, HCV, Janssen

Janssen Pharmaceuticals has acquired one of GlaxoSmithKline’s investigational hepatitis C treatments and will look at it in combination with various …

News
Hospira image

Hospira’s Inflectra approved in Europe

September 10, 2013
Research and Development, Sales and Marketing Hospira, Janssen, Remicade, biosimilars, inflectra

Hospira has been the first firm to meet the European Commission’s approval for a biosimilar monoclonal antibody therapy with its …

News
Janssen image

Women in the pharma industry

September 3, 2013
Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Janssen, Johnson and Johnson, adams, women

In the past pharma has been accused of being too male-orientated in both the laboratory and the boardroom. The idea …

Feature

Boehringer celebrates 50,000 Facebook ‘likes’

August 22, 2013
Medical Communications, Sales and Marketing Boehringer Ingelheim, Facebook, Janssen, Psoriasis 360, likes

News
Remicade image

Remicade copies set for European entry

July 1, 2013
Sales and Marketing CHMP, Hospira, Janssen, Remicade, arthritis, biosimilar

Janssen’s Remicade could soon come under generic pressure after a landmark recommendation by the CHMP. South Korean biotech Celltrion and …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025